• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于甲状腺激素受体的高亲和力亚型选择性激动剂配体。

A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor.

作者信息

Chiellini G, Apriletti J W, Yoshihara H A, Baxter J D, Ribeiro R C, Scanlan T S

机构信息

Department of Pharmaceutical Chemistry, University of California, San Francisco 94143-0446, USA.

出版信息

Chem Biol. 1998 Jun;5(6):299-306. doi: 10.1016/s1074-5521(98)90168-5.

DOI:10.1016/s1074-5521(98)90168-5
PMID:9653548
Abstract

BACKGROUND

Thyroid hormones regulate many different physiological processes in different tissues in vertebrates. Most of the actions of thyroid hormones are mediated by the thyroid hormone receptor (TR), which is a member of the nuclear receptor superfamily of ligand-activated transcription regulators. There are two different genes that encode two different TRs, TR alpha and TR beta, and these two TRs are often co-expressed at different levels in different tissues. Most thyroid hormones do not discriminate between the two TRs and bind both with similar affinities.

RESULTS

We have designed and synthesized a thyroid hormone analog that has high affinity for the TRs and is selective in both binding and activation functions for TR beta over TR alpha. The compound, GC-1, was initially designed to solve synthetic problems that limit thyroid hormone analog preparation, and contains several structural changes with respect to the natural hormone 3,5,3'-triiodo-L-thyronine (T3). These changes include replacement of the three iodines with methyl and isopropyl groups, replacement of the biaryl ether linkage with a methylene linkage, and replacement of the amino-acid sidechain with an oxyacetic-acid sidechain.

CONCLUSIONS

The results of this study show that GC-1 is a member of a new class of thyromimetic compounds that are more synthetically accessible than traditional thyromimetics and have potentially useful receptor binding and activation properties. The TR beta selectivity of GC-1 is particularly interesting and suggests that GC-1 might be a useful in vivo probe for studying the physiological roles of the different thyroid hormone receptor isoforms.

摘要

背景

甲状腺激素调节脊椎动物不同组织中的许多不同生理过程。甲状腺激素的大多数作用是由甲状腺激素受体(TR)介导的,TR是配体激活转录调节因子的核受体超家族成员。有两个不同的基因编码两种不同的TR,即TRα和TRβ,这两种TR在不同组织中常以不同水平共表达。大多数甲状腺激素对这两种TR没有区分,以相似的亲和力与两者结合。

结果

我们设计并合成了一种对TR具有高亲和力的甲状腺激素类似物,它在结合和激活功能上对TRβ比对TRα具有选择性。化合物GC-1最初是为解决限制甲状腺激素类似物制备的合成问题而设计的,相对于天然激素3,5,3'-三碘-L-甲状腺原氨酸(T3)含有几个结构变化。这些变化包括用甲基和异丙基取代三个碘,用亚甲基连接取代联芳基醚连接,并用氧乙酸侧链取代氨基酸侧链。

结论

本研究结果表明GC-1是一类新型拟甲状腺化合物的成员,这类化合物比传统拟甲状腺化合物更易于合成,并且具有潜在有用的受体结合和激活特性。GC-1对TRβ的选择性特别有趣,表明GC-1可能是研究不同甲状腺激素受体亚型生理作用的有用体内探针。

相似文献

1
A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor.一种用于甲状腺激素受体的高亲和力亚型选择性激动剂配体。
Chem Biol. 1998 Jun;5(6):299-306. doi: 10.1016/s1074-5521(98)90168-5.
2
Alternative ligands for thyroid hormone receptors.甲状腺激素受体的替代配体。
Mol Cell Endocrinol. 2019 Aug 1;493:110448. doi: 10.1016/j.mce.2019.05.007. Epub 2019 May 14.
3
Hormone selectivity in thyroid hormone receptors.甲状腺激素受体中的激素选择性
Mol Endocrinol. 2001 Mar;15(3):398-410. doi: 10.1210/mend.15.3.0608.
4
Triiodothyroacetic acid has unique potential for therapy of resistance to thyroid hormone.三碘甲状腺乙酸在治疗甲状腺激素抵抗方面具有独特的潜力。
J Clin Endocrinol Metab. 1995 Jul;80(7):2033-40. doi: 10.1210/jcem.80.7.7608251.
5
X-ray crystallographic and functional studies of thyroid hormone receptor.甲状腺激素受体的X射线晶体学及功能研究
J Steroid Biochem Mol Biol. 1998 Apr;65(1-6):133-41. doi: 10.1016/s0960-0760(98)00029-6.
6
Identification of naturally occurring dominant negative mutants of thyroid hormone alpha 1 and beta 1 receptors in a human hepatocellular carcinoma cell line.在人肝癌细胞系中鉴定甲状腺激素α1和β1受体的天然显性负性突变体。
Endocrinology. 1996 Oct;137(10):4073-81. doi: 10.1210/endo.137.10.8828459.
7
Structure of the carboxy-terminal region of thyroid hormone nuclear receptors and its possible role in hormone-dependent intermolecular interactions.甲状腺激素核受体羧基末端区域的结构及其在激素依赖性分子间相互作用中的可能作用。
Biochemistry. 1995 Aug 22;34(33):10591-9. doi: 10.1021/bi00033a034.
8
Structural determinants of selective thyromimetics.选择性甲状腺激素模拟物的结构决定因素。
J Med Chem. 2003 Jul 3;46(14):3152-61. doi: 10.1021/jm0301181.
9
Synthesis and biological activity of novel thyroid hormone analogues: 5'-aryl substituted GC-1 derivatives.新型甲状腺激素类似物的合成与生物活性:5'-芳基取代的GC-1衍生物
Bioorg Med Chem. 2002 Feb;10(2):333-46. doi: 10.1016/s0968-0896(01)00284-x.
10
Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1.甲状腺受体配体。1. 对甲状腺受体β1具有选择性的激动剂配体。
J Med Chem. 2003 Apr 24;46(9):1580-8. doi: 10.1021/jm021080f.

引用本文的文献

1
Lipid Hormones at the Intersection of Metabolic Imbalances and Endocrine Disorders.代谢失衡与内分泌紊乱交叉点上的脂质激素
Curr Issues Mol Biol. 2025 Jul 18;47(7):565. doi: 10.3390/cimb47070565.
2
An improved synthesis of TRβ-selective thyromimetic GC-1.TRβ选择性甲状腺模拟物GC-1的改进合成方法。
Sci Rep. 2025 Jul 23;15(1):26779. doi: 10.1038/s41598-025-12379-8.
3
Drug discovery targeting thyroid hormone receptor (THR) for the treatment of liver diseases and other medical indications.以甲状腺激素受体(THR)为靶点进行药物研发,用于治疗肝脏疾病及其他医学适应症。
Acta Pharm Sin B. 2025 Jan;15(1):35-51. doi: 10.1016/j.apsb.2024.07.025. Epub 2024 Aug 2.
4
Thyroid hormone receptor beta (THRβ1) is the major regulator of T3 action in human iPSC-derived hepatocytes.甲状腺激素受体β(THRβ1)是人类诱导多能干细胞衍生肝细胞中T3作用的主要调节因子。
Mol Metab. 2024 Dec;90:102057. doi: 10.1016/j.molmet.2024.102057. Epub 2024 Oct 29.
5
Resmetirom: A Systematic Review of the Revolutionizing Approach to Non-alcoholic Steatohepatitis Treatment Focusing on Efficacy, Safety, Cost-Effectiveness, and Impact on Quality of Life.雷斯美洛:关于非酒精性脂肪性肝炎治疗的革命性方法的系统评价,重点关注疗效、安全性、成本效益及对生活质量的影响
Cureus. 2024 Sep 22;16(9):e69919. doi: 10.7759/cureus.69919. eCollection 2024 Sep.
6
TRβ activation confers AT2-to-AT1 cell differentiation and anti-fibrosis during lung repair via KLF2 and CEBPA.TRβ 激活通过 KLF2 和 CEBPA 赋予 AT2 向 AT1 细胞分化和抗纤维化作用,从而促进肺修复。
Nat Commun. 2024 Oct 7;15(1):8672. doi: 10.1038/s41467-024-52827-z.
7
Thyroid Hormone Receptors as Tumor Suppressors in Cancer.甲状腺激素受体作为癌症中的肿瘤抑制因子。
Endocrinology. 2024 Aug 27;165(10). doi: 10.1210/endocr/bqae115.
8
Synthesis and preclinical testing of a selective beta-subtype agonist of thyroid hormone receptor ZTA-261.甲状腺激素受体ZTA - 261的选择性β亚型激动剂的合成与临床前测试
Commun Med (Lond). 2024 Aug 6;4(1):152. doi: 10.1038/s43856-024-00574-z.
9
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors and Hypothyroidism: An Analysis of the Japanese Pharmacovigilance Database.缺氧诱导因子脯氨酰羟化酶抑制剂与甲状腺功能减退症:日本药物警戒数据库分析。
In Vivo. 2024 Mar-Apr;38(2):917-922. doi: 10.21873/invivo.13519.
10
A Systematic Review and Meta-Analysis of Free Triiodothyronine (FT3) Levels in Humans Depending on Seasonal Air Temperature Changes: Is the Variation in FT3 Levels Related to Nonshivering Thermogenesis?根据季节性气温变化对人体游离三碘甲状腺原氨酸(FT3)水平的系统评价和荟萃分析:FT3水平的变化与非寒战产热有关吗?
Int J Mol Sci. 2023 Sep 13;24(18):14052. doi: 10.3390/ijms241814052.